Susan Halabi

Dec 11, 2024 | nature.com | Todd P. Knutson |Bin Luo |Michael Morris |Himisha Beltran |Emmanuel S. Antonarakis |Andrew Armstrong | +1 more

AbstractCirculating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant prostate cancer (mCRPC), ctDNA assays are needed to prognosticate outcomes of patients treated with androgen receptor (AR) inhibitors.

Jun 11, 2024 | urotoday.com | Susan Halabi

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Susan Halabi, who is joining me from Duke, also joining me from ASCO 2024, where she presented a wonderful oral abstract looking at prognostication and risk factors for patients with metastatic castration-resistant prostate cancer within an Alliance trial. Thank you so much for being here with me today. Susan Halabi: I'm delighted to be here. Thank you, Dr. Morgans, for having me.

May 21, 2024 | europeanurology.com | Praful Ravi |Wanling Xie |Marc E. Buyse |Susan Halabi |Philip W. Kantoff |Oliver Sartor

Aug 15, 2023 | brnw.ch | Susan F. Slovin |Karen Knudsen |Susan Halabi |Renee de Leeuw

CONTEXTKey ObjectiveIs the frontline combination of abiraterone acetate/prednisone and cabazitaxel (AAP + C) in comparison with AAP alone beneficial to patients with metastatic castration-resistant prostate cancer (mCRPC) who are naïve to chemotherapy or androgen receptor signaling inhibitors?

Jun 23, 2023 | urotoday.com | Susan Halabi

Read the Full Video TranscriptAndrea Miyahira: Hi everyone, I'm Dr. Andrea Miyahira here and I'm the senior director of Global Research and Scientific Communications at the Prostate Cancer Foundation. Joining me today is Dr. Susan Halabi, a professor of biostatistics and bioinformatics at Duke University. Susan Halabi: Hi, good afternoon. Thank you so much, Andrea, for having me today. Andrea Miyahira: Yeah, so wonderful to have you here.